Outcomes of intra-arterial therapy in major trials
| Study | Mean Baseline NIHSS | Recanalization (TIMI 2 or 3) | Good Outcome at 90 Days (mRS 0–2) | Mortality at 90 Days | Symptomatic ICH |
|---|---|---|---|---|---|
| Intra-arterial therapy | |||||
| PROACT9 | 17 | 58% | NA | 27% | 15% |
| PROACT II6 | 17 | 66% | 40% | 25% | 10% |
| IMS-I8 | 18 | 56% | 43% | 16% | 6% |
| IMS-II5 | 19 | 60% | 46% | 16% | 10% |
| MERCI7 | 22 | 46% | 28% | 44% | 8% |
| Multi MERCI4 | 19 | 68% | 36% | 34% | 10% |
| Penumbra pivotal study | 18 | 82% | 25% | 33% | 11% |
| Nonarterial therapy | |||||
| PROACT9 | 19 | 14% | NA | 43% | 7% |
| PROACT II2 control | 17 | 18% | 25% | 27% | 2% |
| NINDS placebo*5 | 18 | NA | 28% | 24% | 1% |
| NINDS IV rtPA*5 | 18 | NA | 39% | 21% | 7% |
Note:—NIHSS indicates National Institutes of Health Stroke Scale; TIMI, Thrombolysis in Myocardial Infarction trial; ICH, intracranial hemorrhage; mRS, modified Rankin Scale; PROACT, Prolyse in Acute Cerebral Thromboembolism trial; IMS, Interventional Management of Stroke trials; MERCI, Mechanical Embolus Removal in Cerebral Ischemia trials; NINDS, National Institute of Neurological Disorders and Stroke; NA, not available.
* NINDS is subgroup of patients with an NIHSS of 10 or more.